In addition, loss-of-function mutations in Janus kinase 1 (JAK1) or Janus kinase 2 (JAK2) can lead to resistance to PD-1 therapy in melanoma by blocking the IFN-γ signal (58). Here, PDCD1 is linked to melanoma.